合肥产全国首款干细胞新药获批

日前，位于合肥高新区的安徽中盛溯源生物科技有限公司研发的“NCR100注射液”获批临床，拟开展针对膝骨关节炎的临床试验，这也是国内首款获批临床的诱导多能干细胞（iPSC）衍生的间充质干细胞（iMSC）药物^[1]。

图1 合肥产全国首款干细胞新药获批

膝关节炎是中老年人常见的关节退行性病变。骨关节炎是以关节软骨破坏及关节边缘和软骨下骨质再生为特征的慢性关节疾病。本病病理核心是关节软骨的损伤及骨赘形成。目前认为本病是多因素联合作用的结果：软骨基质合成与分解代谢失调，软骨下骨板损害使软骨失去缓冲作用，关节内局灶性炎症^[2]。临床常见患者膝关节的疼痛、晨僵、肿胀、摩擦音及畸形，严重影响了中老年人的生活质量。

图2 膝关节炎病因

一些因子抑制半胱氨天冬氨酸蛋白酶的裂解从而参与炎症调节过程。iPSC-MSCs已经成为骨髓源、脐带源等MSCs和再生药物治疗骨关节炎的一种很有前途的替代细胞来源^[8]。iPSC-MSCs治疗骨关节炎的研究很多，其疗效，副作用及其作用机制也在进一步确认和深入研究中。

图3 iPS细胞分化潜能

参考文献

[1] https://www.cde.org.cn/main/xxgk/listpage/9f9c74c73e0f8f56a8bfbc646055026d

[2] Helmick CG, Felson DT, Lawrence RC, Gabriel S, Hirsch R, Kwoh CK, Liang MH, Kremers HM, Mayes MD, Merkel PA, Pillemer SR, Reveille JD, Stone JH; National Arthritis Data Workgroup. Estimates of the prevalence of arthritis and other rheumatic conditions in the United States. Part I. Arthritis Rheum. 2008 Jan;58(1):15-25. doi: 10.1002/art.23177. PMID: 18163481.

[3] Finckh A, Gilbert B, Hodkinson B, Bae SC, Thomas R, Deane KD, Alpizar-Rodriguez D, Lauper K. Global epidemiology of rheumatoid arthritis. Nat Rev Rheumatol. 2022 Sep 6. doi: 10.1038/s41584-022-00827-y. Epub ahead of print. PMID: 36068354.

[4] Grassi W, De Angelis R, Lamanna G, Cervini C. The clinical features of rheumatoid arthritis. Eur J Radiol. 1998 May;27 Suppl 1:S18-24. doi: 10.1016/s0720-048x(98)00038-2. PMID: 9652497.

[5] Debreova M, Culenova M, Smolinska V, Nicodemou A, Csobonyeiova M, Danisovic L. Rheumatoid arthritis: From synovium biology to cell-based therapy. Cytotherapy. 2022 Apr;24(4):365-375. doi: 10.1016/j.jcyt.2021.10.003. Epub 2022 Jan 26. PMID: 35090806.

[6] El-Jawhari JJ, El-Sherbiny YM, Jones EA, McGonagle D. Mesenchymal stem cells, autoimmunity and rheumatoid arthritis. QJM. 2014 Jul;107(7):505-14. doi: 10.1093/qjmed/hcu033. Epub 2014 Feb 10. PMID: 24518000; PMCID: PMC4071294.

[7] Bačenková D, Trebuňová M, Morochovič R, Dosedla E, Findrik Balogová A, Gašparová P, Živčák J. Interaction between Mesenchymal Stem Cells and the Immune System in Rheumatoid Arthritis. Pharmaceuticals (Basel). 2022 Jul 28;15(8):941. doi: 10.3390/ph15080941. PMID: 36015088; PMCID: PMC9416102.

[8] De Miguel MP, Fuentes-Julián S, Blázquez-Martínez A, Pascual CY, Aller MA, Arias J, Arnalich-Montiel F. Immunosuppressive properties of mesenchymal stem cells: advances and applications. Curr Mol Med. 2012 Jun;12(5):574-91. doi: 10.2174/156652412800619950. PMID: 22515979.